“Microdosing” GLP-1 drugs: a trend, not a protocol — what the dose-response evidence actually says

“Microdosing” GLP-1 drugs is one of the fastest-spreading ideas in the weight-loss corner of the internet: take a dose of semaglutide or tirzepatide well below the labeled, studied range — a fraction of a “real” dose — and capture some of the benefit while sidestepping the cost and the side effects. It is worth being direct about what this is. It is a trend, not an evidence-based protocol. There are no outcome trials of intentional microdosing. What we do have is a clear picture of how these drugs behave across doses, and that picture is the whole point of this piece.

What people mean by it — and why they do it

There is no single definition, which is part of the problem. In practice “microdosing” refers to taking a dose deliberately below what the trials and the label used — sometimes a fraction of the lowest labeled dose, sometimes just staying at an initiation dose indefinitely. The motivations are understandable and, taken on their own terms, reasonable-sounding. Some people want appetite help without the nausea, vomiting and diarrhea that come with the full regimen; the arc of those symptoms is laid out in our GLP-1 GI side-effect timeline. Others are trying to stretch expensive medication further. Others have already lost weight and want a low “maintenance” dose to hold the line. And plenty simply want “just a little” help, not a full pharmacological intervention.

None of those goals is unreasonable. The question is whether a sub-therapeutic dose actually delivers on them — and that is exactly where the evidence runs out.

The pharmacology: efficacy is dose-related

The central fact about GLP-1 receptor agonists for weight is that their effect scales with dose. This is not incidental to how the trials were run — it is the reason they were run the way they were. In a dedicated dose-ranging Phase 2 trial, semaglutide produced progressively greater weight loss as the dose increased across the tested range, with the largest reductions at the highest doses.^[1]The pivotal STEP program then took the drug to a 2.4 mg weekly maintenance dose, where it produced mean weight loss of roughly 15% — after a deliberate multi-week titration up to that dose.^[2]

Tirzepatide shows the same shape even more explicitly. In SURMOUNT-1, the three maintenance doses (5, 10 and 15 mg weekly) produced stepwise-larger weight loss — roughly 15%, 19% and 21% — a textbook dose-response relationship.^[3] The mechanistic and head-to-head differences between the two drugs are covered in our tirzepatide versus semaglutide comparison. The takeaway that matters here is simple: the trials titrate up to therapeutic doses precisely because efficacy is dose-related. Lower doses were not left on the table by accident; they were left because they do less.

The starting dose is already a sub-therapeutic dose

This is the piece that microdosing discussions tend to miss. The labeled starting doses are sub-therapeutic — on purpose. Semaglutide (Wegovy) begins at 0.25 mg weekly, roughly a tenth of the 2.4 mg maintenance dose, and the label prescribes a stepwise escalation over about four months to reach it.^[4] Tirzepatide (Zepbound) starts at 2.5 mg weekly for four weeks before escalation toward a 5, 10 or 15 mg maintenance dose.^[5] Those initiation doses exist to let the gut adapt and reduce early nausea — they are a launchpad, not a destination. A person who stays at an initiation dose, or goes below it, is not on a lower-intensity version of the studied regimen; they are sitting at a point on the curve that the trials treated as a transient step, not an endpoint.

The honesty point: no outcome trials of microdosing

Here is the claim that should anchor everything else: there are no outcome trials of intentional microdosing. Every efficacy figure quoted for these drugs — the 15%, the 21%, the metabolic and cardiovascular benefits — comes from studies that used full, titrated, therapeutic doses. The magnitude of benefit at a deliberately sub-therapeutic dose is simply unproven. It might be modest. It might be negligible for a given person. It might, for some, be meaningful. But “might” is the operative word, because no one has run the trial. Even the maintenance question — whether a lower dose can hold weight already lost — has only been studied as continuation of a therapeutic dose, not as a drop to a microdose. In the trials, stopping or sharply reducing the drug was generally followed by weight regain, which cuts against the intuition that a token dose will effortlessly maintain results.^[6]

The compounding caveat

Microdosing is largely a compounded-product phenomenon. Branded pens come in fixed dose increments that do not lend themselves to taking a small custom fraction, so the practice is mostly enabled by compounded semaglutide and tirzepatide drawn from vials. That matters because compounded products sit in a different regulatory category from FDA-approved branded drugs, with different oversight of potency, purity and labeling — the distinctions are detailed in our compounded versus branded GLP-1 explainer. When the dose is already unstudied and being measured by the user, product-quality uncertainty compounds the efficacy uncertainty rather than offsetting it.

The honest bottom line

The impulses behind microdosing — fewer side effects, lower cost, gentle maintenance, “just a little” help — are legitimate. What is not legitimate is treating a sub-therapeutic dose as a proven, lower-key version of the studied regimen. The pharmacology says efficacy tracks dose; the labels already use their lowest doses as temporary stepping stones; and no trial has measured what intentional microdosing actually delivers. Anyone considering it should do so with a clinician and with clear eyes about which parts are established (the dose-response relationship, the escalation design) and which are entirely unstudied (the benefit of staying low on purpose). This article does not offer a microdosing dose protocol, because there is no evidence base from which to build one.